Loading stock data…
NVO
$43.88+1.66 (+3.93%)
Market ClosedLast close May 1
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novo Nordisk A/S in the Healthcare sector is trading at $43.88. The stock is currently near its 52-week low of $35.12, remaining 9.3% below its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why NVO maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$43.88
Potential Upside
173%
Whystock Fair Value$119.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Buy
Mean target$46.64+6.3%
Range$36.05 – $65.83
Fundamentals
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$175.96B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
10.79
Beta
Defensive asset. Lower volatility than the S&P 500.
0.27
Div Yield
Strong income play. Yield provides a meaningful total return floor.
457.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
57.24%
Volume
Today's trading volume
25.46M
Recent News
Oral Ozempic US Launch And Partnerships Test Novo Nordisk Valuation
Novo Nordisk (CPSE:NOVO B) is rolling out its oral Ozempic (semaglutide) tablet across the US as the only FDA approved oral GLP-1 for adults with type 2 diabetes. The company plans broad distribution through more than 70,000 US pharmacies. New access partnerships with WW International and GoodRx aim to support patients through digital health tools, discounts and self pay options. The launch includes a mix of insurance coverage pathways and cash pay programs targeting both insured and self...
There's Another Twist In The Obesity Pills Showdown — And This One Actually Helps Lilly
The prescription data collected for Eli Lilly's new weight-loss pill, Foundayo, is flawed, analysts said Friday.
Novo Nordisk Launches Ozempic Pill in U.S.
Oral version targets broader access as GLP-1 demand grows
Novo Launches Ozempic Pills Across 70,000 US Pharmacies
Novo will sell 1.5 mg, 4 mg and 9 mg Ozempic pills as it rebrands Rybelsus in the US.
Novo Nordisk rolls out Ozempic pill in the U.S.
Oral version expands access to diabetes therapy